S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed limited stage small cell lung cancer (SCLC)
• Evidence of disease by CT scan of the chest
• Measurable or evaluable disease outside of area of prior surgical resection
• No malignant pericardial or pleural effusions (cytologically positive effusions or exudative effusions not attributable to other etiologies)
• No CNS disease by chest CT scan or MRI
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Zubrod 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• Not specified
• Renal
• Creatinine no greater than upper limit of normal OR
• Creatinine clearance at least 60 mL/min
• Other
• No prior hypersensitivity or contraindication to monoclonal antibody 11D10 anti-idiotype vaccine (TriAb), monoclonal antibody GD2 anti-idiotype vaccine (TriGem), or aluminum hydroxide
• No known sensitivity to rodent proteins (i.e., anti-OKT-3, ONCOSCINT scan)
• No grade 1 or greater symptomatic sensory neuropathy
• No other malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer in complete remission, or any other cancer for which patient has been disease free for 5 years
• If significant clinical hearing loss already present, must accept risk of further hearing loss
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior biologic therapy for SCLC
• No prior TriAb or TriGem
• No prior murine antibodies
• No prior mouse proteins
• At least 30 days since prior immunotherapy
• At least 30 days since any prior immunization
• Chemotherapy
• No prior systemic chemotherapy for SCLC
• No concurrent cyclophosphamide or methotrexate
• Endocrine therapy
• At least 30 days since prior systemic corticosteroids
• No concurrent systemic corticosteroids (except as an antiemetic)
• Radiotherapy
• No prior radiotherapy to the thorax or neck region
• No concurrent intensity modulated radiotherapy
• Surgery
• See Disease Characteristics
• At least 2 weeks since prior thoracic or other major surgery and recovered
• Other
• At least 30 days since prior investigational agents or devices
• No other concurrent investigational agents
• No other concurrent immunosuppressants (e.g., cyclosporine)
• No concurrent chronic systemic antihistamines
• No concurrent amifostine